南财智讯6月14日电，百利天恒公告，注射用BL-M14D1（DLL3ADC）收到国家药品监督管理局签发的《药物临床试验批准通知书》（通知书编号：2026LP01761），同意本品开展联合PD-1/PD-L1单抗±抗血管生成药物±化疗治疗广泛期小细胞肺癌的临床试验。（文章来源：南方财经网）
Source Link南财智讯6月14日电，百利天恒公告，注射用BL-M14D1（DLL3ADC）收到国家药品监督管理局签发的《药物临床试验批准通知书》（通知书编号：2026LP01761），同意本品开展联合PD-1/PD-L1单抗±抗血管生成药物±化疗治疗广泛期小细胞肺癌的临床试验。（文章来源：南方财经网）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.